Lead Sponsor

AstraZeneca

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•Signed informed consent
•Age ≥ 40 years
•Patients fulfilling criteria for COPD according to the Global initiative for chronic obstructive pulmonary disease (GOLD) stage I or higher
•Smokers or ex-smokers of at least 10 pack-years
•Patients suffering an AECOPD either:
•1. Admitted to hospital due to AECOPD (severe exacerbation) or
•2. Confirmed AECOPD at GP (general practitioner) setting (moderate exacerbation) Definition AECOPD: Increase in respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both.

•Patients who have never smoked
•Patients with active long-term respiratory disease (e.g. bronchial asthma, cystic fibrosis, severe bronchiectasis, malignancy, restrictive lung diseases etc.)
•Exacerbation of COPD due to other causes such as pneumothorax and acute decompensated congestive heart failure
•Difficulties in communication (cognitive deterioration, sensorial disability, language barriers)
•Severe disease with poor vital prognosis (life length expectancy less than one year)

Related studies

NCT06847061 · Chronic Obstructive Pulmonary Disease (COPD

NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07383896 · Asthma, COPD

NCT07112235 · COPD (Chronic Obstructive Pulmonary Disease), Rhinovirus Infection, and more

NCT07518472 · Pulmonary Disease, Chronic Obstructive (COPD)

Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations